Vesicare OD, a muscarine receptor antagonist discovered and developed by Astellas, was approved for an additional formulation of the overactive bladder treatment with the indication of urinary frequency, urgency and urge incontinence associated with overactive bladder (OAB).
Vesicare relaxes bladder smooth muscles and improves symptoms associated with OAB such as urinary frequency, urgency and urge incontinence by blocking muscarine receptors on bladder’s smooth muscles.
Astellas said that Vesicare OD is the OAB treatment developed using WOWTAB which is the company’s proprietary drug delivery technology.
Additionally, Astellas offers Gaster D for the treatment for peptic ulcers and gastritis and Harnal D for the treatment of functional symptoms of benign prostatic hyperplasia which used WOWTAB technology.
Astellas expects to further contribute to the treatment of OAB by introducing Vesicare OD into the Japanese market, which can further improve the compliance with its convenient dosing option.